ArticleAIChE journal. American Institute of Chemical Engineers2014
Evaluation of Nanoparticle Tracking for Characterization of Fibrillar Protein Aggregates.
Article in AIChE journal. American Institute of Chemical Engineers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 32 citations in OpenAlex.
- Effect of controlled release of HGF on extracellular vesicle secretion by urine-derived stem cells.Frontiers in bioengineering and biotechnology · 2024Article
- Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy.Cancer cell international · 2022Review
- Multispectral Nanoparticle Tracking Analysis for the Real-Time and Label-Free Characterization of Amyloid-β Self-Assembly In Vitro.Analytical chemistry · 2020Article
- Validation of Size Estimation of Nanoparticle Tracking Analysis on Polydisperse Macromolecule Assembly.Scientific reports · 2019Article
- Retinol-Binding Protein Interferes with Transthyretin-Mediated β-Amyloid Aggregation Inhibition.Biochemistry · 2018Article
- Nanoparticle Tracking for Protein Aggregation Research.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Two-dimensional flow nanometry of biological nanoparticles for accurate determination of their size and emission intensity.Nature communications · 2016Article
- TANGO-Inspired Design of Anti-Amyloid Cyclic Peptides.ACS chemical neuroscience · 2016Article
- Transthyretin variants with improved inhibition of β-amyloid aggregation.Protein engineering, design & selection : PEDS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Amyloidogenesis is the process of formation of protein aggregates with fibrillar morphology. Because amyloidogenesis is linked to neurodegenerative disease, there is interest in understanding the mechanism of fibril growth. Kinetic models of amyloidogenesis require data on the number concentration and size distribution of aggregates, but this information is difficult to obtain using conventional methods. Nanoparticle tracking analysis (NTA) is a relatively new technique that may be uniquely suited for obtaining these data. In NTA, the two-dimensional (2-D) trajectory of individual particles is tracked, from which the diffusion coefficient, and, hence, hydrodynamic radius is obtained. Here we examine the validity of NTA in tracking number concentration and size of DNA, as a model of a fibrillar macromolecule. We use NTA to examine three amyloidogenic materials: beta-amyloid, transthyretin, and polyglutamine-containing peptides. Our results are instructive in demonstrating the advantages and some limitations of single-particle diffusion measurements for investigating aggregation in protein systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.